Summary
Background Measurement of disease activity guides treatment of chronic spontaneous urticaria (CSU). A weekly Urticaria Activity Score -here, the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7 TD ) -measures severity from 0 to 42. Insufficient evidence exists on whether disease activity states, defined by categorical UAS7 TD scores, correlate with other patient-reported outcomes and treatment response. Objectives To evaluate and compare categorical UAS7 TD scores with selected measures of disease-related quality of life and impact. Methods Data from three randomized clinical trials of omalizumab in CSU were pooled. Continuous UAS7 TD scores were categorized into five disease activity states: urticaria-free, well-controlled, mild, moderate and severe urticaria. Total scores from the Dermatology Life Quality Index; the Chronic Urticaria Quality of Life questionnaire; and questions on sleep and daily activity interference, presence of angioedema and diphenhydramine use were compared within categorized UAS7 TD disease-state scores, using ANOVA for analysis at different time points and mixedeffects regressions for analysis of all data pooled. Results Pooled analyses showed that categorical UAS7 TD disease states accurately predicted differences among treated patients with CSU with different levels of disease activity. A consistent pattern existed between categories, with higheractivity disease states associated with significantly higher impact and an increase in angioedema frequency. Results at different treatment time points were consistent. Conclusions Categorical UAS7 TD disease states can discriminate between measures when considering the impact of urticaria activity. Using five categorical disease states could simplify clinical assessment and monitoring of treatment efficacy.
What is already known about this topic?
• Increased urticaria disease activity, as measured by the continuous twice-daily Urticaria Activity Score -the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7 TD ) -impacts health-related quality of life and interferes with sleep and daily activity.
What does this study add?
• Categorizing continuous UAS7 TD activity scores into disease states defined by UAS7 TD score ranges can discriminate between different levels of disease activity, simplify clinical assessment and facilitate evaluation of treatment efficacy.
Chronic spontaneous (also known as idiopathic) urticaria (CSU) is defined as the occurrence of itchy wheals/hives, angioedema or both for > 6 weeks with or without known causes.
1 CSU is known to have a substantial impact on the patient's quality of life (QoL), including effects on daily living activities and work productivity, and by causing sleep disturbance, loss of energy and emotional problems.
2,3
Various types of patient-reported outcome (PRO) measures are used to assess CSU disease activity and its impact on daily activities and health-related QoL (HRQoL). 4 CSU activity is assessed based on the occurrence of signs (wheals/hives) and symptoms (pruritus/itch). As the appearance of hives and the intensity of itch can change on a daily basis, assessment of both is best performed by patients with the daily Urticaria Activity Score (UAS), summed to a weekly score (UAS7). 5, 6 In addition, the impact of CSU on HRQoL can be measured with dermatological-specific measures, such as the Dermatology Life Quality Index (DLQI) 7 and the urticaria-specific Chronic Urticaria Quality of Life Questionnaire (CU-Q 2 oL). 8 The UAS is recommended for routine clinical practice; 1 however, it may be challenging to compare patients in terms of their disease activity using the continuous scoring of the UAS. It could be useful to know whether grouping the continuous score of the UAS7 into a smaller number of categories that would reflect different levels of CSU activity, or disease states, could discriminate among patients with CSU with different levels of disease activity. Specifically, there is insufficient evidence as to whether disease states defined by categorical UAS7 scores correlate with CSU disease activity and response to treatment. If categorical UAS7 disease states could be shown to be informative with regard to the impact of disease on patients' life, QoL and response to treatment, they could be an efficient tool for clinical practice. The purpose of this initial validation of these CSU activity categories was to describe categorical UAS7 scores in terms of DLQI and CU-Q 2 oL scores, as well as selected measures of disease activity and impact, and to assess whether a clear, significant discrimination exists between the categories.
Materials and methods

Data
Data for the analysis came from three randomized, doubleblind, placebo-controlled phase III global clinical trials [ASTERIA I (n = 319); 9 ASTERIA II (n = 323); 10 GLACIAL (n = 336) 11 ] evaluating the effect of omalizumab on symptoms of patients with inadequately controlled CSU. Figure 1 presents the treatment and follow-up periods of the trials, as well as the dosing regimens and timing of the PRO data collection for the three trials. Patients in the ASTERIA I and II trials received licensed doses of second-generation H 1 antihistamines as background therapy, 9,10 whereas patients recruited into the GLACIAL study received second-generation H 1 antihistamines (up to four times the licensed dose), H 2 blockers and/or leukotriene receptor antagonists. 11 Treatment was administered once every 4 weeks for 24 weeks in ASTERIA I and GLACIAL, 9, 11 and for 12 weeks in ASTERIA II. 10 All three trials had a follow-up period with no active treatment of 16 weeks. The studies conformed to the Declaration of Helsinki. 12 All studies were ethically approved and all patients gave informed consent.
Measures
Three primary PRO measures, capturing signs and symptoms, dermatological QoL and disease-specific QoL, were used to obtain information on patients' experiences with CSU in the clinical trials: the twice-daily version of the UAS over 7 days (UAS7 TD ) 6 as part of the Urticaria Patient Daily Diary (UPDD); 13 the DLQI; 7,14 and the CU-Q 2 oL. 8 
Urticaria Patient Daily Diary
The validated UPDD contains the UAS (assessed every 12 h) and daily activity interference, sleep interference and presence of angioedema, all of which are assessed every 24 h, as well as the use of rescue medication.
13
Twice-daily version of the Urticaria Activity Score over 7 days. In the UAS7 TD , patients record the morning and evening itch severity score (ISS) and hives scores. ISS is assessed each time as 0 (no itch), 1 (mild), 2 (moderate) and 3 (severe), and the number of hives is assessed as 0 (none), 1 (1-6 hives); 2 (7-12 hives); and 3 (> 12 hives). A daily UAS score is obtained from the sum of the average daily ISS and average daily hives score. The weekly UAS7 TD score is obtained by summing the daily UAS scores over 7 days. Scores were reported at baseline and every 4 weeks until week 40 for ASTERIA I and GLA-CIAL, 9, 11 and until week 28 for ASTERIA II.
disease states: urticaria-free (UAS7 TD = 0), well-controlled urticaria (UAS7 TD = 1-6), mild-activity urticaria (UAS7 TD = 7-15), moderate-activity urticaria (UAS7 TD = 16-27) and severe activity urticaria (UAS7 TD = 28-42). 15 Two of these disease states (urticaria-free and well-controlled urticaria) were predefined end points for the clinical trials. Patients had to have a UAS7 TD score of ≥ 16 to be included in the trials, so 16 was considered the lower threshold for the moderate disease state. In addition, a score of ≥ 28 was considered severely active disease. 16 The remaining UAS7 TD scores (i.e. 7-15) were used to define a mild urticaria disease state. All categorical ranges of scores were developed with expert input.
15,17
Additional questions in the Urticaria Patient Daily Diary. Several additional questions collected in the UPDD were included to make comparisons among the UAS7 TD disease states. In the diary, patients were asked to rate how much their hives and itch interfered with sleep and with daily activities during the previous 24 h (0 = no interference; 1 = mild, little interference; 2 = moderate, some interference; and 3 = substantial, severe interference). Patients were asked whether they had used antihistaminic rescue medications [number of diphenhydramine (DPH) 25-mg pills] during the previous 24 h to control symptoms of their skin condition, such as hives or itch (0-3 pills). Finally, patients were asked about the presence of angioedema (yes or no) in the previous 24 h. For the sleep, daily activities and medication items, the mean of the sum of the daily scores for the 7 days prior to the study visit of interest was calculated (range 0-21, with higher score indicating higher impact). For the presence of angioedema, patients were categorized as 'yes' if they responded yes to the angioedema question on any of the 7 days prior to the visit of interest. The weekly mean scores on all items were used as comparison variables to test whether different UAS7 TD disease states were characterized by different mean scores on these parameters' comparison variables.
Dermatology Life Quality Index
The DLQI has a total score that ranges from 0 to 30, 7 with higher scores reflecting worse HRQoL. The recall period for the DLQI is 1 week. DLQI data were collected at baseline and weeks 4, 12, 24 and 40 for ASTERIA I and GLACIAL, 9,11 and at baseline and weeks 4, 12 and 28 for ASTERIA II. 10 The DLQI has been validated for use in patients with CSU. 7, 14, 18 Validated score ranges exist for the DLQI to explain the impact on dermatological-related QoL: no effect (0-1); small effect (2-5); moderate effect (6-10); very large effect (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) ; extremely large effect (21-30).
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Chronic Urticaria Quality of Life Questionnaire
The CU-Q 2 oL is a disease-specific, 23-item PRO measure designed to assess HRQoL in patients with CSU. 8, 20 The recall period is 2 weeks. Patients are asked how bothered they have been by each symptom in the previous 2 weeks. Each item is assessed on a 5-point scale ranging from 1 (never) to 5 (very much). The total score is transformed to range from 0 to 100, with higher scores indicating worse HRQoL. CU-Q 2 oL data were collected at baseline and weeks 4, 12, 24 and 40 for ASTERIA I and GLACIAL, 9, 11 and at baseline and weeks 4, 12
and 28 for ASTERIA II. 10 
Data analyses
Exploratory analyses of individual trials at different time points
Initial analyses of data, by individual trial at different time points, were performed by simple descriptive statistics (means, SDs, proportions) for each of the measures detailed in the previous subsection. These analyses were conducted using available data at each time point, as they were exploratory in nature and the results were specific point estimates (e.g. means, proportions). The results of these analyses indicated a pattern: as UAS7 TD disease-state activity increased, the scores on the comparator variables, such as the DLQI and CU-Q 2 oL, became worse (Tables S1-S4 ; see Supporting Information). In addition, cross-tabulations of the UAS7 TD disease states with the DLQI response categories, as well as with changes in DLQI effect sizes, were conducted and significance testing conducted with Pearson's v 2 (Tables S5-S13; see Sup- porting Information). The means of continuous UAS7 TD scores for each DLQI effect size were then examined using one-way ANOVA with Bonferroni correction for multiple pairwise comparisons to see if adjacent DLQI effect sizes had significantly different mean UAS7 TD scores (Tables S14-S17 ; see Supporting Information). The number of patients in each subgroup was insufficient to provide robust summary statistics; however, because the patient population (Table 1) and study design ( Fig. 1) were similar, data were pooled to increase sample size.
Pooled data analyses
Comparison of twice-daily version of the Urticaria Activity Score over 7 days disease states with comparator variables at different time points. Trial data were pooled (all trials, all treatment arms) and assessed at baseline, 12 weeks and end of study (week 40 for ASTERIA I and GLACIAL, 9,11 and week 28 for ASTERIA II 10 ). UAS7 TD disease states were compared on the following measures: DLQI total score, CU-Q 2 oL total score, sleep interference, activity interference, number of DPH pills and the proportion of patients with angioedema in the previous 7 days. At 12 weeks, comparison of the proportion of angioedema-free days from weeks 4 to 12 was also assessed. Mean scores of selected comparator variables for adjacent UAS7 TD disease states were compared using one-way ANOVA. Bonferroni correction for multiple comparisons helped guard against significant differences in mean scores for each comparator variable between UAS7 TD disease states arising as a result of chance. To add to our conservative approach, comparisons for statistically significant differences were limited to adjacent disease states only, such that patients who were in the urticaria-free disease state (UAS7 TD = 0) were compared with those in the well-controlled urticaria disease state (UAS7 TD = 1-6); those in the well-controlled urticaria disease state (UAS7 TD = 1-6) were compared with those in the mild urticaria disease state (UAS7 TD = 7-15) and so forth.
Prediction of outcomes by twice-daily version of the Urticaria Activity Score over 7 days disease states. A second set of analyses were conducted in which all trials, all treatment arms and all time points were pooled. The data were analysed using mixed-effects regression models (linear mixed models across multiple time points with fixed effects for baseline covariates) to predict selected outcomes by UAS7 TD disease states. UAS7 TD disease states were used to predict, separately, the DLQI total score, the CU-Q 2 oL total score, sleep interference, activity interference, the number of DPH pills and the number of days with angioedema. Trial and treatment arm were included in the models as fixed effects. Covariates included sex, age and duration of disease. The health state of 'urticaria-free' (i.e. UAS7 TD = 0) was used as the reference category for each initial mixedeffects regression model predicting the selected outcome. Each analysis then used these regression estimates to calculate the marginal mean scores and standard errors (SEs) for the selected outcome, for each UAS7 TD disease state, adjusted for the covariates in the model. For exploratory descriptive analyses, observed data were used. Predictive analyses were conducted on two datasets: first using the pooled trials datasets in which missing data were accounted for by applying multiple imputation method; and, second, on the observed data, under the assumption that the missing data mechanism was missing at random. P-values of ≤ 0Á05 were considered significant. All analyses were conducted using Stata (version 13Á0 or higher; Stata Corp., College Station, TX, U.S.A.).
Results
Baseline characteristics
A total of 975 patients were available for analysis: 318 from ASTERIA I, 322 from ASTERIA II and 335 from GLACIAL. The demographic and baseline characteristics of the study population are shown in Table 1 . The majority (72-76%) were female, with a median age ranging from 41 to 44 years and a mean disease duration of approximately 7 years. The populations across the three trials were similar, with no significant differences found, except that a greater proportion of patients presented with baseline angioedema in GLACIAL than in ASTERIA II.
10,11
Categorical twice-daily version of the Urticaria Activity Score over 7 days disease states distinguish patients with different quality of life impairments Pooled trial analyses confirmed that categorical UAS7 TD disease states can accurately predict differences in QoL impairment. When all trials, all treatment arms and all time points were pooled, the differences between each adjacent disease state were highly significant (P ≤ 0Á001) in the DLQI and CU-Q 2 oL total scores [ Fig. 2a, b ; Tables S1-S18 (see Supporting Information)], with a 50-100% increase in HRQoL scores between improving UAS7 TD disease states. We found similar results by pooled trial analyses at different time points, particularly after 12 weeks of treatment and at the study-end assessment, that is, 16 weeks following end of treatment (Tables S1-19 ; see Supporting Information). A consistent pattern was revealed: the greater the disease activity, the higher the impact on HRQoL, and this impact was independent of type and duration of treatment. Categorical twice-daily version of the Urticaria Activity Score over 7 days disease states are associated with disease impact on daily activities and sleep
The impact of disease activity on daily activities and interference with sleep was significantly different for each category band of UAS7 TD disease states and doubled consistently between each subsequent increase in disease activity [ Fig. 3a,  b ; Tables S1-S18 (see Supporting Information)]. These differences were also consistently significant at different time points in treatment (Tables S1-S19; see Supporting Information), indicating that control of CSU activity allows patients to carry out their normal daily activities without sleep deprivation.
Categorical twice-daily version of the Urticaria Activity Score over 7 days disease states reflect use of ondemand antihistamine medication
The use of DPH rescue medication increased significantly as the categorical UAS7 TD disease activity increased [ Fig. 4 ; Tables S1-S18 (see Supporting Information)]. Patients in the severe urticaria score band (UAS7 TD = 28-42) required four times the number of DPH pills as those patients with wellcontrolled or no urticaria (UAS7 TD ≤ 6). Again, these results were seen at different time points (Tables S1-S19; see Supporting Information); however, significance was not consistent, particularly between the lower-activity disease states. Effect of chronic spontaneous urticaria on on-demand antihistamine therapy in the previous 7 days, by categorical Urticaria Activity Score for the past 7 days, assessed twice daily (UAS7 TD ) disease states. Pooled data with multiple imputation of missing data mixed-effects regression analysis. Significance shown to the next-worst disease state. DPH, diphenhydramine.
Higher twice-daily version of the Urticaria Activity Score over 7 days disease states are linked to higher prevalence rates of reported angioedema
The pooled trial analyses showed that the higher categorical disease activity states are generally associated with significantly higher rates of reported days with angioedema when looking at data pooled across trials, time points and all patients. These rates rise noticeably with a UAS7 TD score > 15 [ Fig. 5 ; Tables S1-S18 (see Supporting Information)]. At different time points (e.g. weeks 12 and 40), the pattern of increased rates of angioedema in higher categorical disease activity states was also seen, but most differences were nonsignificant (Tables S1-S19 in Supporting Information).
Results using observed data were similar, both with all data pooled (Tables S1-S20; see Supporting Information) and at different time points (Tables S1-S21 ; see Supporting Information).
Discussion
This study assessed whether patients with different categorical UAS7 TD scores, reflecting different levels of CSU activity, have significantly different levels of HRQoL impairment, interference with daily activities and sleep, use of on-demand medications and prevalence of angioedema. Our findings indicated that this is the case: patients with different categorical UAS7 TD have significantly different disease impacts on their daily lives. Thus, these five UAS7 TD disease states can significantly differentiate patients with CSU in terms of the effects that CSU has on their lives. Patients with lower UAS7 TD categories have better-controlled CSU, less angioedema, significantly better QoL and experience less interference with daily activities and sleep. These analyses also showed that, irrespective of the treatment a patient receives, a patient with a specific disease activity, as measured by the five categorical UAS7 TD disease states, will have a particular HRQoL and that this HRQoL will be significantly different from that of a patient with another disease activity state.
The results of the pooled analyses, where mixed-effects regressions were performed for all patients, all treatment arms and all time points, showed a consistent pattern: comparison variable scores were statistically significantly better (P ≤ 0Á05) for each improved UAS7 TD disease state, with the majority of the tests significant at P ≤ 0Á001.
Previous analyses have shown a near-perfect correlation between changes in signs and symptoms of CSU, as measured by the UAS7 TD , and changes in the DLQI and CU-Q 2 oL over the same time period. 21 These analyses provide further evidence of the strength of these relationships, even when assessed in categorical activity states. This first empirical look at disease states in CSU measured by itch and hives also provided new evidence that angioedema should be considered when analysing the experiences of patients with CSU and that angioedema increases with increased disease activity, particularly moderate-to-severe CSU activity. Because there was concern that comparisons among multiple UAS7 TD disease states on multiple comparator variables would result in multiplicity and yield significant differences among disease states simply by chance, a limited number of selected variables were used for statistical comparisons, and only comparisons on the effects of urticaria between adjacent disease states were conducted. Mean scores on comparator variables were consistently worse for increasingly worse health states. Significance tests demonstrated the extent to which UAS7 TD disease states were statistically different on these selected variables and added confidence to the hypothesis that the UAS7 TD disease states can discriminate among patients in terms of their urticaria activity.
Perhaps the main limitation of this study is related to the analyses at specific time points. With the exception of robust results at week 12, not all differences at other time points were statistically significant, most likely owing to small sample sizes. However, when all data were pooled, consistent and significant differences were seen. Further analyses, including sensitivity analyses using bands based on different UAS7 TD scores and alternative anchor tools, such as visual analogue scores, to evaluate itch would lend additional support to these UAS7 TD disease states. 22 As noted earlier, the exploratory analyses made no adjustment for missing data. This was done intentionally, as using only available data allowed comparison of actual observed patient experiences by UAS7 TD health states. For the predictive Fig 5. Angioedema in the previous 7 days, by categorical Urticaria Activity Score for the past 7 days, assessed twice daily (UAS7 TD ) disease states. Pooled data with multiple imputation of missing data; mixed-effects regression analysis. Significance shown to the next-worst disease state. models using mixed-effects regressions, analyses were performed two ways: multiple imputation for missing data and using only available, observed data. Results were very similar and conclusions were the same in either case. The main difference in results was that there were more significant differences using the multiply imputed data. This is not surprising given the larger sample size that resulted from imputing data. Thus, as expected, using only available data is a more conservative approach, which supports the UAS7 TD health states' ability to discriminate between patient experiences with urticaria.
One potential consideration of relevance to this research relates to the instruments used in measuring CSU. Some aspects of the psychometric properties of the DLQI (e.g. dimensionality and differential item function) have been criticized; 23 however, the DLQI has been validated for use in CSU, 14, 24, 25 and a minimally important difference has been determined. 18, 26 The CU-Q 2 oL, a relatively recent addition to the study of HRQoL in CSU, is recommended as the diseasespecific assessment tool by the international guidelines. 1 These disease states were obtained using the UAS7 TD . However, international guidelines also have a preference for use of a once-daily (UAS7 OD ) version of UAS. 1 The UAS7 OD 5 differs from the UAS7 TD 6 in that the itch and hive assessment is conducted once every 24 h and in the number of hives included in the daily hive score. The daily itch and hives score ranges are the same (0-3) in both versions, as are the scoring and weekly ranges (0-42) (Tables S1-S20 ; see Supporting Information), but differ in the number of 24-h hives that compose the same daily hives score. Further studies examining the equivalency of the UAS7 TD scores with scores obtained with UAS7 OD are ongoing. Overall, our results suggested that categorizing continuous UAS7 TD score ranges into categorical UAS7 TD disease states can discriminate between different levels of urticaria activity. Different levels of disease activity correlated with PROs. A pattern of greater consistently significant impact on HRQoL, daily activities, sleep and use of on-demand antihistamine treatment was seen with each higher UAS7 TD category. Reducing the continuous UAS7 TD score from 42 points to five categorical disease states, much like the DLQI scoring bands, 19 could simplify clinical assessment and facilitate evaluation of treatment efficacy. Further research and analyses of these correlations is warranted.
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